Targeted MRI and chemotherapy of ovarian cancer with clinic available nano-drug based nanoprobe

Cancer is the leading cause of death worldwide, and chemotherapy, as its main treatment, has side effects in clinical application due to lack of targeting selectivity to tumor tissues. Theranostic nanomaterials have shown wonderful functions for the diagnosis and therapy of disease benefitting from the controllability of nanomaterials. However, there is still little available for clinical transformation due to the uncertain biocompatibility. It is urgent to develop nanoprobes possessing bright transformation potentials. This study reports a facile biomineralization route to synthesize the theranostic nanoprobe using the clinic available nano-drug (trademark Abraxane). Further profiting from the binding ability of albumin to metal cations, we successfully prepared biocompatible nanoprobe, BSA-Gd2O3/[email protected] mAb, for the targeted magnetic resonance imaging and chemotherapy of ovarian carcinoma. The obtained nanoprobe has the advantages of uniform particle size, good dispersibility and favorable stability. In vivo and in vitro experiment results showed that the nanoprobe can realize targeted magnetic resonance imaging and chemotherapy of ovarian carcinoma. Such a novel multifunctional nanoprobe based on clinic nano-drug might be promising for clinic transformation.